There are currently 2667 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Longitudinal Study of Urea Cycle Disorders
NCT00237315
Recruiting
Urea cycle disorders (UCD) are a group of rare inherited metabolism disorders. Infants and children with UCD commonly experience episodes of vomiting, lethargy, and coma. The purpose of this study is to perform a long-term analysis of a large group of individuals with various UCDs. The study will focus on the natural history, disease progression, treatment, and outcome of individuals with UCD.
Gender:
ALL
Ages:
All
Trial Updated:
02/10/2024
Locations: Children's Hospital Boston (UCDC New England Center), Boston, Massachusetts
Conditions: Brain Diseases, Metabolic, Inborn, Amino Acid Metabolism, Inborn Errors, Urea Cycle Disorders
Register for Updates
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
NCT05639556
Recruiting
The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies inclu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Massachusetts General Hospital (MGH), Boston, Massachusetts +1 locations
Conditions: Cystic Fibrosis
Register for Updates
MOLAR: Mapping Oral Health and Local Area Resources
NCT05688982
Recruiting
The goal of this clinical trial is to test the impact of a screening and linkage intervention for adverse social determinants of health (aSDoH) on oral health linkage to care for emergency department patients. Researchers will compare three groups: Patients in Arm A will receive paper handouts with general oral health and aSDoH resources. Patients in Arm B will receive paper handouts with geographically-proximate oral health and aSDoH resources. Patients in Arm C will receive geographically-prox... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
02/09/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Dental Diseases
Register for Updates
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
NCT06132165
Recruiting
This study will evaluate the effectiveness of skin cooling in increasing tolerability of four treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a 755nm laser, radio-frequency injection, and a Kybella injection. Each patient will have a treatment and a control site..
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/07/2024
Locations: Wellman Center for Photomedicine, Boston, Massachusetts
Conditions: Neurofibromatosis 1
Register for Updates
Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation
NCT05995899
Recruiting
The aim of this study is to better understand how tenapanor affects the metagenomics and metabolomics of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor is the newest FDA-approved agent for IBS-C. It is a small molecule that inhibits the NHE3 receptor, leading to impaired sodium and water absorption in the intestine. Previous clinical trials comparing tenapanor to placebo showed that a 50 mg dose of tenapanor led to increased bowel movements and decreased abdominal pa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/07/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: IBS, IBS - Irritable Bowel Syndrome
Register for Updates
fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
NCT04439552
Recruiting
Evaluation of neuroplasticity of pain pathways and corneal afferent nerve regeneration following corneal crosslinking (CXL) in keratoconus patients using fMRI and corneal In Vivo Confocal Microscopy (IVCM).
Gender:
ALL
Ages:
Between 8 years and 35 years
Trial Updated:
02/07/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Pain, Postoperative, Pain, Chronic, Pain, Acute, Surgical Injury, Surgical Wound, Cornea Injury, Cornea, Keratoconus
Register for Updates
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
NCT04215809
Recruiting
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/06/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: CLL/SLL
Register for Updates
Interstage Monitoring Using an Implantable Loop Recorder: A Pilot Study
NCT05744934
Recruiting
The primary objective of this investigation is to evaluate the feasibility and safety of implantable loop recorder implantation (using the LUX-DX™) in newborns undergoing stage 1 palliation. The secondary objective of the investigation is to evaluate the feasibility of continuous measurement of heart rate and arrhythmia using an implantable loop recorder (LUX-Dx™) during the interstage period. An implantable loop recorder will be placed at the time of chest closure following stage 1 palliation... Read More
Gender:
ALL
Ages:
30 days and below
Trial Updated:
02/06/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Univentricular Heart
Register for Updates
Orphan Europe Carbaglu® Surveillance Protocol
NCT03409003
Recruiting
The purpose of this study is to conduct post-marketing surveillance of carglumic acid (Carbaglu) to obtain long-term clinical safety information. Carglumic acid was approved by the United States Food and Drug Administration (FDA) for treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Much of the FDA-required data is already collected through the Longitudinal Study of Urea Cycle Disorders (RDCRN Protocol #5101). This study will collect additional data on advers... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/06/2024
Locations: Children's Hospital Boston (UCDC New England Center), Boston, Massachusetts
Conditions: N-acetylglutamate Synthase (NAGS) Deficiency
Register for Updates
Strength After Breast Cancer
NCT06052488
Recruiting
The goal of this study is to explore whether a group exercise program called Strength After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve physical function among women after treatment for breast cancer. The main questions this study aims to answer are: * Can the Strength After Breast Cancer program and the associated outcome battery be successfully delivered in an outpatient physical therapy clinic at Massachusetts General Hospital and do participants find... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: MGH Institute of Health Professions, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors.
NCT05547321
Recruiting
Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab in the treatment of patients with advanced or metastatic cancer in whom there is no available standard therapeutic option.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Advanced Solid Tumor
Register for Updates
Studying Pathways of Resistance in KRAS-driven Cancers
NCT05272423
Recruiting
Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally and submitted to Foundation Medicine, Inc. (FMI), for the FoundationOne® Liquid Biopsy Assay. Patients who have had resistance mechanisms determined through other assays can also consent to share these data. The Investigator(s) will compare mechanisms of acquired resistance across drugs (e.g. sotorasib vs adagrasib) and between tumor types (e.g. NSCLC vs CRC) to determine if di... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: KRAS P.G12C
Register for Updates